|Articles|June 5, 2017

Evoke Pharma Enters Agreement with Rho CRO to Submit NDA

Evoke Pharma, Inc.-a pharma company focused on treatments for gastrointestinal diseases-announced an agreement with Rho, Inc.-a regulatory consulting and contract research organization (CRO).

Rho and Evoke will collaborate with the preparation and submission of Evoke's planned 505(b)(2) New Drug Application (NDA) for Gimoti™-the company’s nasal delivery formulation of metoclopramide, which helps relieve symptoms associated with acute and recurrent diabetic gastroparesis in adult women.

Read the full release here.

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Evoke Pharma Enters Agreement with Rho CRO to Submit NDA

Related Content

Vaccine Trials at an Inflection Point: Operational, Regulatory, and Public Trust Challenges

ACT Brief: Cross-Asset Site Partnerships, Vaccine Trial Standardization, and Ovarian Cancer Care Gaps

A Shot in the Arm to Traditional Vaccine Trial Strategy

SCOPE X: How AI Could Reshape the Sponsor-Site Relationship Over the Next Several Years

ACT Brief: Site-First Technology Strategy, AI Data Harmonization Architecture, and Obesity Trial Retention

Trending on Applied Clinical Trials Online

The Data Harmonization Imperative: How AI Is Solving Clinical Research's Biggest Bottleneck

ACT Brief: Cross-Asset Site Partnerships, Vaccine Trial Standardization, and Ovarian Cancer Care Gaps

SCOPE X: How AI Could Reshape the Sponsor-Site Relationship Over the Next Several Years

A Shot in the Arm to Traditional Vaccine Trial Strategy

Patient Engagement Strategies in Anti-Obesity Medication Clinical Trials: Addressing Drop Out Rate and Improving Retention